The North America Sepsis Diagnostics Market would witness market growth of 7.0% CAGR during the forecast period (2022-2028).
These data analytics technologies have made it possible to combine several test findings from many platforms, allowing for real-time access to data and precise detection of diseases. In addition, various technological advances have resulted in the development of novel immunological and molecular biomarkers that can be used to detect sepsis early. Following this, the market for sepsis diagnostics is being driven by increased investments in comprehensive R&D initiatives, which include innovative blood culture methodologies for diagnosing and treating chronic infections. Sepsis is a catastrophic situation that happens when one or more organs fail.
Rapid detection is very important for patient survival because the survival probability drops by a notable rate for every hour when antimicrobial therapy is delayed. Many of the SOFA criteria, such as blood analyzers, also necessitate facilities and testing equipment that may not be provided in improvement of the healthcare communities. Due to these limitations, a simpler, single test for diagnosing sepsis at the point of care that can substitute the SOFA score without lowering accuracy would be preferred.
Point of care (POC) thermal techniques on bimolecular analysis give a client or health professional immediately, actionable information at the time and location of assessment and treatment. These technologies are often low-cost, simple-to-use, and quick, with lesser infrastructure requirements, making them useful in a wide range of situations across the world. Small sample quantities, such as a fingerprick blood sample, portable standalone devices, as well as the most basic lab equipment, such as microscopes, are all possible with POC technology.
There is a substantial presence of a larger patient population as well as a growing geriatric population in this region. Moreover, this region comprises well-established insurance policies and a robust healthcare infrastructure.
According to Sepsis alliance, more than 1.7 million people in the United States are diagnosed with sepsis each year, one in every 20 seconds, and the incidence is increasing at an annual rate of 8%, with hospitalization costs in the United States exceeding USD 27 billion. According to statistics, the region's market growth is boosted by a growing patient population and high disposable income. Additionally, according to the Centers for Disease Control and Prevention, approximately 1.7 million adults in the United States were estimated to diagnose with sepsis in August 2021, with nearly 270,000 Americans dying as a result. It was also shown that sepsis affects one out of every 3 patients who die in a hospital. As a result of the high estimated incidence of the condition in the country, the market will benefit from increased diagnosis.
The US market dominated the North America Sepsis Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2018; thereby, achieving a market value of $226.3 million by 2028. The Canada market is poised to grow at a CAGR of 9.5% during (2022 - 2028). Additionally, The Mexico market would display a CAGR of 8.5% during (2022 - 2028).
Based on Method, the market is segmented into Conventional and Automated. Based on Test Type, the market is segmented into Laboratory Tests and Point-of-Care Tests. Based on Pathogen, the market is segmented into Bacterial Sepsis, Fungal Sepsis, Viral Sepsis, and Others. Based on Product, the market is segmented into Blood Culture Media, Assays & Reagents, Instruments, and Software. Based on End-User, the market is segmented into Hospitals & specialty clinics, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes. Based on Technology, the market is segmented into Blood Culture, Immunoassays, Molecular Diagnostics, Flow Cytometry, Microfluidics, and Biomarkers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Sepsis Diagnostics MarketMarket is Estimated to reach $879.5 Million by 2028, at a CAGR of 8.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Bruker Corporation, Siemens Healthineers AG, Danaher Corporation, and Quidel Corporation.
By Method
By Test Type
By Pathogen
By Product
By End-User
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
